Global Drug-Resistant Tuberculosis Treatment Market Growth (Status and Outlook) 2025-2031

The global Drug-Resistant Tuberculosis Treatment market size is predicted to grow from US$ 2383 million in 2025 to US$ 3286 million in 2031; it is expected to grow at a CAGR of 5.5% from 2025 to 2031.

Drug-resistant tuberculosis (DR-TB) treatment refers to the medical interventions and therapies used to manage and combat tuberculosis (TB) infections caused by strains of the Mycobacterium tuberculosis bacteria that are resistant to one or more of the standard anti-TB drugs. DR-TB is a significant global health concern because it poses challenges for effective TB control and requires more complex and prolonged treatment regimens compared to drug-susceptible TB. There are different categories of DR-TB, including multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), each with its own treatment protocols.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LPI (LP Information)' newest research report, the “Drug-Resistant Tuberculosis Treatment Industry Forecast” looks at past sales and reviews total world Drug-Resistant Tuberculosis Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected Drug-Resistant Tuberculosis Treatment sales for 2025 through 2031. With Drug-Resistant Tuberculosis Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Drug-Resistant Tuberculosis Treatment industry.

This Insight Report provides a comprehensive analysis of the global Drug-Resistant Tuberculosis Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Drug-Resistant Tuberculosis Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Drug-Resistant Tuberculosis Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drug-Resistant Tuberculosis Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drug-Resistant Tuberculosis Treatment.

This report presents a comprehensive overview, market shares, and growth opportunities of Drug-Resistant Tuberculosis Treatment market by product type, application, key players and key regions and countries.

Segmentation by Type:
First-Line Anti-TB Drugs
Second-Line Anti-TB Drugs
Others

Segmentation by Application:
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sanofi
Novartis AG
Endo International plc
CMP Pharma
STI Pharma LLC
Akorn Incorporated
Lupin
Johnson & Johnson Services Inc.
Macleods Pharmaceuticals Ltd
Pfizer Inc
Hikma Pharmaceuticals PLC
Lannett
Mylan N.V.
Teva Pharmaceutical Industries Ltd
Fresenius Kabi AG

Please note: The report will take approximately 2 business days to prepare and deliver.